OTC · Biotechnology

Karolinska Development AB (publ) (KDEVF) Stock

$0.26 +0.00% OTC: KDEVF Healthcare

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry.

Valuation

MetricValue
Price$0.26
Market Cap$68.85M
P/E Ratio-0.34
P/B Ratio0.11
P/S Ratio23.88
EPS (TTM)$-0.58
52-Week High$0.61
52-Week Low$0.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-19.50%
ROA-19.24%
ROCE-19.28%
Gross Margin81.84%
Operating Margin-1763.64%
Net Margin-1754.55%
Debt/Equity0.00
Current Ratio128.29

Annual Financials (USD)

Metric20202021202220232025
Revenue$3.0M$2.0M$2.0M$3.0M$11.0M
Operating Profit$-202.0M$161.0M$-87.0M$-2.0M$-194.0M
Net Profit$-207.0M$171.0M$-88.0M$5.0M$-193.0M
EPS$-1.05$0.86$-0.34$0.02$-0.58
Op Margin-7635.8%7405.5%-3800.9%-68.1%-1797.3%

Balance Sheet (USD)

Metric20202021202220232025
Total Assets$890.0M$1.1B$1.3B$1.3B$1.1B
Total Liabilities$90.0M$138.0M$10.0M$12.0M$8.0M
Cash$76.0M$42.0M$131.0M$85.0M$24.0M
Borrowings$77.0M$125.0M$1.0M$3.0M$1.0M

Latest News

TowneBank Q2 Earnings, Revenue Rise MT Newswires · Jul 23, 2026 Renault says sales stalled in first half AFP · Jul 23, 2026 Should You Buy Amazon and Meta Platforms Stocks Before July 29? Motley Fool · Jul 23, 2026 argenx Q2 Profit, Total Operating Income Rise MT Newswires · Jul 23, 2026 STMicroelectronics Q2 Non-GAAP Earnings, Revenue Rise MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric20202021202220232025
Operating Cash Flow$-33.0M$17.0M$-33.0M$-25.0M$-26.0M
Investing Cash Flow$-5.0M$-56.0M$-114.0M$79.0M$9.0M
Financing Cash Flow$-1.0M$-1.0M$-20.0M$-1.0M$-1.0M
Net Cash Flow$24.0M$-33.0M$89.0M$-46.0M$-11.0M
Free Cash Flow$-96.0M$10.0M$-33.0M$74.0M$-26.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.48
FCF Yield-36.23%
Quick Ratio128.29
Interest Coverage-6905.13
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BSTGBiostage, Inc. $4.03 +0.75% -9.83 $57.82M 0.00%
EOFBYEcofibre Limited $0.84 +0.00% -0.17 $73.67M 0.00%
ETXPFE-therapeutics Plc $0.13 +0.00% -4.71 $75.96M 0.00%
HRPMFHerantis Pharma Oyj $3.51 +0.00% -6.09 $59.47M 0.00%
KIARFKiaro Holdings Corp. $0.00 — 0.00 $442 0.00%

About Karolinska Development AB (publ)

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.

Karolinska Development AB (publ) is headquartered in SE.

Karolinska Development AB (publ) (KDEVF) stock trades at $0.26 with a market capitalization of $68.85M. The stock is valued at a price-to-earnings (P/E) ratio of -0.34, price-to-book of 0.11, price-to-sales of 23.88. Over the past 52 weeks the stock has ranged between $0.26 and $0.61, and currently trades 57.4% below its 52-week high.

On profitability, Karolinska Development AB (publ) generates a return on equity (ROE) of -19.50%, return on capital employed of -19.28%, an operating margin of -1763.64%, a net profit margin of -1754.55%.

Official website: www.karolinskadevelopment.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides